Appendix C 
NON-TECHNICAL ABSTRACT ; 
Autologous bone marrow transplantation is a technique which 
makes safe the very high doses of chemotherapy and radiation which 
are required to eradicate some populations of the neoplastic cells. 
The marrow is removed from the hip bones of the patient at the time 
of remission, stored and re-infused into the patient after 
intensive systemic therapy in order to restore marrow function. 
Peripheral blood will also be used for the restoration of 
hematopoietic function following bone marrow transplantation. We 
will compare peripheral blood with marrow with respect to their 
ability to promote hematopoietic recovery. It is now impossible to 
determine if relapse arises from residual cells or if residual 
leukemia cells present in systemic circulation after intensive 
therapy can contribute to the relapse. Molecules called "marking 
vectors" can be used to resolve this question, and to evaluate the 
efficacy of purging of marrow stored from chronic lymphocytic 
leukemia (CLL) patients. To accomplish this, a portion of the bone 
marrow and peripheral blood cells stored from the patient will be 
incubated with the marking vector. This vector will introduce a 
new genetic marker into these neoplastic cells. If the neoplastic 
cells appearing at the time of relapse contain the marker, then the 
relapse arose from cells infused with the autologous bone marrow or 
peripheral blood. Thus, in this case, the methods used to remove 
the neoplastic cells from the autologous bone marrow or peripheral 
blood cells used for transplant will be identified as insufficient 
stringency to remove all of the neoplastic cells. In this case, 
more thorough measures can then be undertaken to remove the 
neoplastic cells from the marrow. In this study, the GINa and LNL6 
marking vectors will be used to tag the abnormal cells which may be 
infused into the patient along with the hematopoietic cells used to 
regenerate marrow function after intensive therapy. The GINa and 
LNL6 vectors will also be used to mark the peripheral blood and 
marrow respectively. The results of this study will be used to 
improve the therapy of future patients but will not necessarily 
benefit the patients themselves. 
Recombinant DNA Research, Volume 16 
[411] 
